Prognostic utility of B-type natriuretic peptide and 6-min walk test in patients with acute decompensated heart failure

What Was Tested

This observational study paper looks at BNP (Nesiritide).

The researchers aimed to assess the utility of B-type natriuretic peptide (BNP) and 6-min walk test (6 MWT) together as predictors of re-hospitalization and mortality in acute decompensated heart failure (ADHF) patients.

Who Took Part

The study group was 100 patients.

The age groups tagged for this paper are middle-aged adults, both men and women.

Patients (aged≥18 years) with ADHF and left ventricular systolic dysfunction were included in this study.

The study group (N = 100 patients) consisted of patients undergoing a second BNP test along with the 6 MWT at the time of discharge and at 3-months of discharge.

How the Study Was Run

The timeline in the abstract includes 6 months.

This prospective, observational, comparative study was conducted at a tertiary care center in India between October 2016 and March 2018.

The control group (N = 100 patients) consisted of patients who did not undergo these tests at discharge and/or at 3-months of discharge.

Study endpoints were re-hospitalization within 6-months, and in-patient and 6-month mortality.

What Was Measured

The subject headings attached to it are Heart Failure, Natriuretic Peptide, Brain, Prognosis, Biomarkers, Acute Disease, Walk Test and India.

Author keywords: Mortality.

What This Means in Plain Language

This is a observational study of BNP (Nesiritide) in 100 patients over 6 months.

The abstract goes on to report its results in about 6 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2024 (Indian heart journal), a journal based in India.

More context: the BNP (Nesiritide) compound page, all human trials.